Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Gontran VersetIvan BorbathMark KarwalChris VerslypeHans Van VlierbergheAdel KardoshVittorina ZagonelPer StålDebashis SarkerDaniel H PalmerArndt VogelJulien EdelineStephane CattanMasatoshi KudoAnn-Lii ChengSadahisa OgasawaraBruno DanieleStephen L ChanJennifer J KnoxShukui QinAbby B SiegelMichael ChisamoreKen HatogaiAnran WangRichard S FinnAndrew X ZhuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In patients with advanced HCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- advanced non small cell lung cancer
- phase ii study
- study protocol
- electronic health record
- double blind
- placebo controlled
- squamous cell carcinoma
- big data
- machine learning
- mesenchymal stem cells
- combination therapy
- bone marrow
- cell therapy
- radiation therapy
- smoking cessation
- locally advanced